Niagen Bioscience

12/04/2025

We’re thrilled to see Tru Niagen featured in Glossy as we expand into beauty with the launch of Tru Niagen Beauty.

This new supplement supports hair, skin, and nail health while delivering the NAD+ benefits our customers rely on.

Thank you to journalist Lexy Lebsack for speaking with CEO Rob Fried and Niagen’s Dr. Andrew Shao to highlight the science behind the product.

Read the feature here:
https://bit.ly/4avjGGK

Tru Niagen, the California-based market leader in NAD-support supplements, has expanded into the beauty supplement category. Announced Thursday, the company hopes to attract beauty consumers interested in improving hair, skin and nail health while boosting NAD levels with its new $62 Tru Niagen Beau...

11/27/2025

Join our partners at Niagen Bioscience for a healthcare practitioner exclusive in-depth discussion on pivotal new research in long COVID recovery.⁠
⁠
This webinar will explore “Effects of Nicotinamide Riboside on NAD+ Levels and Cognitive and Symptom Recovery in Long COVID: A Randomized Controlled Trial”—investigating whether nicotinamide riboside supplementation can help improve cognitive function and symptom recovery.⁠
⁠
📆 December 3 | 11:30am PST⁠
🔗 Register via link in bio

11/21/2025

We’re proud to celebrate Dr. Roger Kornberg, Nobel Prize laureate and chairman of the Niagen Scientific Advisory Board, for receiving an Honorary Doctorate of Science from the Hong Kong University of Science and Technology (HKUST)!

Dr. Kornberg’s pioneering work in molecular biology and gene transcription continues to inspire our mission to advance cellular health and longevity through science-backed innovation.

HKUST President Prof. Ip celebrated the honorary doctorates for their accomplishments and profound impact: “Today, we gather not only to confer degrees but also to celebrate the years of vigorous study, unwavering dedication, and the impactful contributions you, our graduates, are already making. This ceremony honors the exceptional individuals you havWe’re honored to celebrate Nobel laureate and Chairman of the Niagen Scientific Advisory Board, Dr. Roger Kornberg earning an Honorary Doctorate of Science from the Hong Kong University of Science and Technology!

His groundbreaking contributions to molecular biology and gene transcription help drive our mission to push the frontiers of cellular health and longevity.

Congratulations, Dr. Kornberg!

11/18/2025

Long COVID continues to impact millions of Americans:

✦ 43 million U.S. adults have ever experienced long COVID.
✦ 17 million are currently living with it.
✦ Among those who've had COVID-19, approximately 3 in 10 have experienced long COVID at some point, and about 1 in 10 currently have it.

While these numbers show that many people do recover over time, millions continue to experience persistent symptoms that impact their daily lives. This is why continued research into understanding and addressing long COVID remains so critical.

At Niagen Bioscience, we're committed to advancing the science of cellular health to help address conditions like long COVID.

11/17/2025

Long COVID affects an estimated 400 million people worldwide—and there’s still so much to understand about this complex condition.

From persistent fatigue to brain fog, the symptoms can impact multiple systems in the body. But emerging research is uncovering what’s happening at the cellular level—and pointing toward potential pathways for recovery.

Learn more about what long COVID is, its common symptoms, and the science behind it. Link in bio.

11/14/2025

A new clinical study found that nicotinamide riboside (NR) supplementation was associated with improvements in brain function, sleep, fatigue, and mood in long COVID patients—with no significant side effects.

In secondary outcomes of this randomized, placebo-controlled trial, participants taking NR daily showed within-individual improvements after 10 weeks. While larger studies are needed, these findings support NR as a potential therapeutic option for long COVID symptom management.

Learn more at the link in our bio.

11/13/2025

New research published in The Lancet’s eClinicalMedicine reveals that Niagen® supplementation significantly boosted NAD+ levels and improved fatigue, sleep quality, depression, and cognitive function in Long COVID patients.

With 400 million people worldwide affected by Long COVID and no proven treatments available, this groundbreaking 58-patient study offers new hope, showing NAD+ levels increased up to 3.1-fold after just 5-10 weeks.

Visit our Investor Relations site via NiagenBioscience.com to learn more. Link in bio.

11/13/2025

Results from the first-of-its-kind clinical trial published in The Lancet peer-reviewed journal eClinicalMedicine demonstrated that daily supplementation with “Niagen Bioscience’s patented nicotinamide riboside (NR) ingredient significantly increased NAD + levels and improved executive functioning, fatigue, depression, and sleep quality, when compared to their baseline levels, in individuals with Long COVID.”
Further research will be needed to establish a therapeutic role, but this groundbreaking study is an exciting and promising step forward.

11/06/2025

Q3 2025 marked another milestone in our journey as the global leader in NAD+ science and innovation.

Total net sales: $34.0M (+33% YoY)
Tru Niagen sales: $26.0M (+44% YoY)
Cash position: $64.3M with zero debt

There’s a better way to age.

11/04/2025

Strong Q3 performance: Niagen Bioscience reported total net sales of $34.0 million, with Tru Niagen sales of $26.0 million—up 33% and 44% year-over-year.

Net income of $4.6 million and reaffirmed increased full year outlook of 25%-30% growth.

We expanded Niagen Plus to 1,000+ clinics and launched AboutNAD, advancing our mission as the global leader in NAD+ science.

10/28/2025

Everyone’s talking about NAD+. But who’s actually doing the research? 🧬

Our SVP of Global Scientific & Regulatory Affairs, Andrew Shao, sat down with HPA-Global to discuss our evolution from ChromaDex to Niagen Bioscience—and the strategic shift it represents.

“We are not a supplement company. We are an NAD+ company.”

This distinction matters. Watch the full interview on HPA Global Insights’ YouTube.

10/21/2025

Niagen Bioscience (NASDAQ: NAGE), the global authority on NAD+ science and healthy-aging research, announces its Q3 2025 earnings call scheduled for Tuesday, November 4 at 4:30 PM ET.

Join management for financial results and strategic updates from the leader in NAD+ innovation.

▸ Conference call dial-in: +1 888 596 4144
▸ Conference ID: 8584242

The earnings call will be broadcast live and available for replay via the investor relations section on niagenbioscience.com.